Skip to content

Design Therapeutics

US · DSGN #3479 by market cap Listed 2021
11.38 -0.31 -2.65%
Live - 5344 symbols - heartbeat 206s ago · 2026-10-08 09:56
Pre-market 11.81 +1.03%
After-hours 11.69 0.00%
Market cap
712.18M
P/B
3.53
EPS
-1.22
Reader sentiment Are you bullish or bearish on DSGN?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/3/10
  • Rating change
    Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20
    Market Newswire · 2026/4/29
  • Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/8/4
  • Rating change
    Jefferies Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15
    Market Newswire · 2026/3/16
  • Rating change
    Oppenheimer Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $18
    Market Newswire · 2026/1/7
  • Rating change
    RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Raises Target Price to $5
    Market Newswire · 2025/3/12
  • Rating change
    RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $14
    Market Newswire · 2026/4/29
  • Rating change
    RBC Capital Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $14
    Market Newswire · 2026/3/10
  • Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22
    Market Newswire · 2026/5/19
  • Rating change
    Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2025/5/9
  • Rating change
    RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5
    Market Newswire · 2025/8/8
  • Rating change
    Craig-Hallum Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15
    Market Newswire · 2025/12/3
  • RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20
    Market Newswire · 2026/5/20
  • Rating change
    Leerink Partners Upgrades Design Therapeutics(DSGN.US) to Buy Rating, Raises Target Price to $14
    Market Newswire · 2025/12/3
  • Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/5/27
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)
    TipRanks · 2026/3/10
  • Rating change
    Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/4/29
  • Rating change
    RBC Capital Upgrades Design Therapeutics(DSGN.US) to Buy Rating, Raises Target Price to $13
    Market Newswire · 2025/11/20
  • Rating change
    Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21
    Market Newswire · 2026/5/4
  • Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/6/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 09:56:28 · For reference only, not investment advice and not tailored to your situation.